Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects

作者：Jeongjun Kim, Jin‐Ho Choi, Hwankyu Kang, Jiye Ahn, Jane Hutchings, Christo van Niekerk, Dongsik Park, Jaeseung Kim, Yeejin Jeon, Kiyean Nam, Soyoung Shin, Beom Soo Shin · 发表于：Antimicrobial Agents and Chemotherapy · 年份：2021 · DOI：10.1128/aac.01436-21 · 被引用次数：39 · 研究领域：Tuberculosis Research and Epidemiology、Mycobacterium research and diagnosis、Cancer therapeutics and mechanisms

Telacebec (Q203) is a potent drug candidate under clinical development for the treatment of drug-naïve and drug-resistant tuberculosis. The first-in-human randomized, placebo-controlled, double-blind, dose-escalation Phase 1A trial (Q203-TB-PI-US001) was conducted to evaluate the safety, tolerability, and pharmacokinetics of telacebec.